INTRODUCTION {#s1}
============

Circular RNAs (circRNAs) are formed by the covalent binding between phosphodiester bonds on their 3' and 5' ends, which are distinct from linear RNAs \[[@R1]--[@R3]\]. Due to the lacking of free ends, circRNAs could escape the effects from exonuclease and ribonuclease, thus they are more stable than linear RNAs in cells \[[@R4]\]. So far, about one hundred thousand circRNAs have been identified which exert extensive functions in human body such as miRNA sponges and gene regulator \[[@R5]--[@R8]\]. There has been mounting evidence that circRNAs play significant roles in tumor genesis, malignant transformation, signal transduction, invasion, metastasis and angiogenesis. For example, circ_100284 could up-regulate the expression of target gene EZH2 by inhibiting miR-217, elevate the concentration of cyclin D1, promote the cell cycle and induce vicious transformation of cells \[[@R9]\]; circ-ITCH may lead to cell cycle arrest and malignant cells suppression by affecting the Wnt signal pathway \[[@R10]\]; circ-Foxo3 could inhibit tumor angiogenesis \[[@R11]\]; ciRS-7 is closely related to hepatic microvascular invasion (MVI) by modulating the expression of miR-7 as well as its target genes, PIK3CD and p70S6K \[[@R12]\]. It has been found that circRNAs expression is highly stable in saliva, blood and exosomes, which could be attributed to the effective mechanisms of their synthesis and elimination in cells \[[@R13]--[@R15]\]. Moreover, circRNAs are relatively abundant both in cells and extracellular fluids with a long half-time period \[[@R13], [@R16]\]. As a result, they are very likely to be biomarkers for cancer diagnosis and prognosis which could provide a promising method for clinical practice \[[@R1], [@R3]\].

Although, in recent years, some certain circRNAs have been reported to act as stable markers for diagnosis and prognosis of cancer, there still are some questions affecting the evaluation of circRNAs in cancer diagnosis and prognosis, including limited number of research cases, skimble-scamble sample source and disease status, various experiment methods and other uncontrolled factors. Therefore, the current research data about the clinic role of circRNAs remains unconvincing. Accordingly, we conducted a systematic review and meta-analysis on the association of circRNAs expression with cancer diagnosis and prognosis for the first time. The study aims to clarify their relationship and the possibility of circRNAs as tumor markers, which could be helpful for clinical decision-making and the development of circRNAs-based targeted therapy.

RESULTS {#s2}
=======

Selection of studies {#s2_1}
--------------------

A total of 1905 records were retrieved initially from databases, and 27 articles were involved in our final meta-analysis after multiple steps of selection (Figure [1](#F1){ref-type="fig"}) \[[@R12], [@R17]--[@R42]\]. Among the enrolled studies, 16 were related to diagnosis \[[@R17], [@R19]--[@R24], [@R26], [@R28], [@R29], [@R34]--[@R39]\], and the others were about prognosis \[[@R12], [@R18], [@R25], [@R27], [@R30]--[@R33], [@R40]--[@R42]\]. These studies referred to 30 kinds of circRNAs in all, 3 of which were focused on the combined effects (four circRNAs: hsa_circRNA_101308, hsa_circRNA_104423, hsa_circRNA_104916, hsa_circRNA_100269; three circRNAs: hsa_circRNA_10219, hsa_circRNA_006054, hsa_circRNA_406697; and two circRNAs: hsa_circRNA_0007874, hsa_circRNA_104135).

![Flow diagram of the study selection process](oncotarget-09-11824-g001){#F1}

Diagnostic meta-analysis of circRNAs in cancers {#s2_2}
-----------------------------------------------

Study characteristics and quality assessment {#s2_3}
--------------------------------------------

The main characteristics of diagnostic studies were shown in Table [1](#T1){ref-type="table"}. Sixteen studies including 1735 cases and 1707 controls were enrolled in the diagnostic meta-analysis. They were all published between February 2015 and September 2017. The main detection method for circRNAs expression was quantitative real-time reverse transcription PCR (qRT-PCR), while only one study applied fluorescence *in situ* hybridization (FISH). Samples in most researches were selected from cancerous and paracancerous tissues taken from surgery, while circRNAs expression in plasma was only detected by a single study. Quality assessment of diagnostic accuracy studies-2 (QUADAS-2) was employed to evaluate the quality of enrolled diagnostic studies. All of them were suggested to have moderate to high quality and thus appropriate for meta-analysis ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

###### The main featurs of the included studies for diagnostic meta-analysis

  Reference number   Auhor                   Year   cirRNAs                                           Country   Ethnicity   Cancer type   Case/Control   Sample   AUC     Se      Sp      Detection methods   Citation
  ------------------ ----------------------- ------ ------------------------------------------------- --------- ----------- ------------- -------------- -------- ------- ------- ------- ------------------- ----------
  1                  Peifei Li et al         2015   hsa_circ_002059                                   China     Asian       GC            101/101        tissue   0.730   0.810   0.620   qRT-PCR             24
  2                  Xuning Wang et al       2015   hsa_circ_001988                                   China     Asian       CRC           31/31          tissue   0.788   0.680   0.730   qRT-PCR             20
  3                  Meilin Qin et al        2016   hsa_circ_0001649                                  China     Asian       HCC           89/89          tissue   0.630   0.810   0.690   qRT-PCR             26
  4                  Xingchen Shang et al    2016   hsa_circ_0005075                                  China     Asian       HCC           30/30          tissue   0.940   0.833   0.900   qRT-PCR             21
  5                  Shijun Chen et al       2017   hsa_circ_0000190                                  China     Asian       GC            104/104        tissue   0.750   0.721   0.683   qRT-PCR             23
  6                  Shijun Chen et al       2017   hsa_circ_0000190                                  China     Asian       GC            104/104        plasma   0.600   0.414   0.875   qRT-PCR             23
  7                  Liyun Fu et al          2017   hsa_circ_0004018                                  China     Asian       HCC           102/129        tissue   0.848   0.716   0.815   qRT-PCR             17
  8                  Wen-han Li et al        2017   hsa circ 0001649                                  China     Asian       GC            76/76          tissue   0.834   0.711   0.816   qRT-PCR             22
  9                  Yongfu Shao et al       2017   hsa_circ_0001895                                  China     Asian       GC            96/96          tissue   0.792   0.678   0.857   qRT-PCR             29
  10                 Zhicheng Yao et al      2017   circZKSCAN1                                       China     Asian       HCC           102/102        tissue   0.834   0.822   0.724   FISH                19
  11                 Peili Zhang et al       2017   hsa_circRNA_103809                                China     Asian       CRC           170/170        tissue   0.669   0.662   0.690   qRT-PCR             28
  12                 Peili Zhang et al       2017   hsa_circRNA_104700                                China     Asian       CRC           170/170        tissue   0.616   0.682   0.532   qRT-PCR             28
  13                 Liyun Fu et al          2017   hsa_circ_0003570                                  China     Asian       HCC           107/107        tissue   0.700   0.449   0.868   qRT-PCR             39
  14                 Yongfu Shao et al       2017   hsa_circ_0014717                                  China     Asian       GC            96/96          tissue   0.696   0.594   0.813   qRT-PCR             37
  15                 Xiaoli Zhu et al        2017   hsa_circ_0013958                                  China     Asian       LAC           49/49          tissue   0.815   0.755   0.796   qRT-PCR             34
  16                 Xiaoli Zhu et al        2017   hsa_circ_0013958                                  China     Asian       LAC           30/30          plasma   0.794   0.667   0.933   qRT-PCR             34
  17                 Lingshuang Lü et al     2017   hsa_circ_100219,hsa_circ_006054,hsa_circ_406697   China     Asian       BrC           51/51          tissue   0.820   0.825   0.732   qRT-PCR             36
  18                 Rongdan Lu et al        2017   hsa_circ_0006633                                  China     Asian       GC            96/96          tissue   0.741   0.600   0.810   qRT-PCR             35
  19                 Kuei-Yang Hsiao et al   2017   circCCDC66                                        China     Asian       CRC           131/76         tissue   0.884   0.927   0.740   qRT-PCR             38

GC=Gastric Cancer; HCC=Hepatocellular Carcinoma; CRC=Colorectal Cancer; NSCLC=Non Small Cell Lung Cancer; LAC: Lung Adenocarcinoma; BC: Breast cancer; AUC=Area Under Curve; Se=Sensitivity; Sp=Specificity; qRT-PCR=Quantitative real time reverse transcription PCR; FISH=fluorescence *in situ* hybridization.

Meta-analysis findings {#s2_4}
----------------------

Among the 18 diagnosis-related circRNAs, 3 was up-regulated (hsa_circ_0005075, hsa_circ_0013958, circCCDC66) and 15 were down-regulated (hsa_circ_002059, hsa_circ_001988, hsa_circ_0001649, hsa_circ_0000190, hsa_circ_0004018, hsa_circ_0001895, circZKSCAN1, hsa_circ_103809, hsa_circ_104700, hsa_circ_003570, hsa_circ_0014717 hsa_circ_100219, hsa_circ_006054, hsa_circ_406697, hsa_circ_0006633, Table [2](#T2){ref-type="table"}, Table [3](#T3){ref-type="table"}). To explore whether circRNAs could serve as effective markers for cancer diagnosis, we calculated the overall sensitivity, specificity and diagnostic odds ratio (DOR), which were 0.71(0.65--0.77), 0.77(0.72--0.81) and 8.37(6.14--11.39), respectively (Figure [2](#F2){ref-type="fig"}). The summary receiver operator characteristic curve (SROC) was shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"} and the corresponding AUC was 0.81(0.77--0.84), suggesting a relatively high accuracy of circRNAs for cancer diagnosis.

###### The main features of the included studies for prognostic meta-analysis

  Referrence number   Author                Year   circRNAs                                                                         Country   Ethnicity   Cancer   Sample   N     Stage   Survival   Follow-up (months)   HR(95%CI)              Detection methods   Citation
  ------------------- --------------------- ------ -------------------------------------------------------------------------------- --------- ----------- -------- -------- ----- ------- ---------- -------------------- ---------------------- ------------------- ----------
  1                   Jie Chen et al        2017   circPVT1                                                                         China     Asian       GC       Tissue   187   I-IV    DFS        85                   0.490(0.330--0.720)    qRT-PCR             30
  2                   Liangliang Xu et al   2017   ciRS7 (Cdr1as)                                                                   China     Asian       HCC      Tissue   95    I-IV    DFS        63                   1.450(0.870--2.410)    qRTPCR              12
  3                   Yan Zhang et al       2017   hsa_circRNA_101308, hsa_circRNA_104423, hsa_circRNA_104916, hsa_circRNA_100269   China     Asian       GC       Tissue   67    III     RFS        12                   6.248(2.534--15.403)   qRT-PCR             25
  4                   Yan Zhang et al       2017   hsa_circRNA_101308, hsa_circRNA_104423, hsa_circRNA_104916, hsa_circRNA_100269   China     Asian       GC       Tissue   52    III     RFS        12                   4.886(1.375--17.359)   qRT-PCR             25
  5                   Jie Chen et al        2017   circPVT1                                                                         China     Asian       GC       Tissue   187   I--IV   OS         83                   0.600(0.400--0.880)    qRT-PCR             30
  6                   Wenhao Weng et al     2017   ciRS-7 − A                                                                       China     Asian       CRC      Tissue   153   I--IV   OS         100                  2.070(1.098--3.902)    qRT-PCR             18
  7                   Wenhao Weng et al     2017   ciRS-7 − A                                                                       Japan     Asian       CRC      Tissue   165   I--IV   OS         133                  2.690(1.257--5.741)    qRT-PCR             18
  8                   Jun-Tao Yao et al     2017   hsa_circRNA_100876                                                               China     Asian       NSCLC    Tissue   101   I--IV   OS         41                   1.000(0.960--1.040)    qRT-PCR             27
  9                   Yan Zhang et al       2017   hsa_circRNA_100269                                                               China     Asian       GC       Tissue   112   III     OS         50                   0.600(0.350--1.020)    qRT-PCR             33
  10                  Dan Han et al         2017   circMTO1 (hsa_circRNA_0007874/hsa_circRNA_104135)                                China     Asian       HCC      Tissue   116   I-IV    OS         80                   0.340(0.220--0.510)    FISH                42
  11                  Zhenyu Zhong et al    2017   circRNA-MYLK                                                                     China     Asian       BC       Tissue   32    I--IV   OS         43                   3.920(1.900--8.100)    qRT-PCR             31
  12                  Xiu-Yan Huang et al   2017   hsa_circRNA_100338                                                               China     Asian       HCC      Tissue   80    I--IV   OS         126                  1.000(0.970--1.03)     qRT-PCR             40
  13                  Haiyan Pan et al      2017   ciRS-7                                                                           China     Asian       GC       Tissue   102   I--IV   OS         60                   2.110(0.940--3.890)    qRT-PCR             32
  14                  Haiyan Pan et al      2017   ciRS-7                                                                           China     Asian       GC       Tissue   154   I--IV   OS         60                   2.630(1.230--5.550)    qRT-PCR             32
  15                  Wenzhi Guo et al      2017   circ-ITCH                                                                        China     Asian       HCC      Tissue   288   I--IV   OS         90                   0.450(0.290--0.680)    qRT-PCR             41

GC=Gastric Cancer; HCC=Hepatocellular Carcinoma; CRC=Colorectal Cancer; NSCLC=Non Small Cell Lung Cancer; BC=Bladder Cancer; N=number of cases; DFS=Disease Free Survival; RFS=Recurrence Free Survival; OS=Overall Survival; HR=hazard ratio; CI=confidence interval; qRT-PCR=Quantitative real time reverse transcription PCR.

###### CircRNAs and roles in cancers

  Reference number   CircRNAs                                            Prognosis         Role         Cancer Type     Function                             Citation
  ------------------ --------------------------------------------------- ----------------- ------------ --------------- ------------------------------------ ----------
  1                  hsa_circ_002059                                     Down-regulation   Suppressor   GC              Metastasis                           24
  2                  hsa_circ_001988                                     Down-regulation   Suppressor   CRC             Invasion/Differentiation             20
  3                  hsa_circ_0001649                                    Down-regulation   Suppressor   HCC             Development/ Progression             26
  4                  hsa_circ_0000190                                    Down-regulation   Suppressor   GC              Occurrence/Progression               23
  5                  hsa_circ_0004018                                    Down-regulation   Suppressor   HCC             Occurrence/Metastasis                17
  6                  hsa circ 0001649                                    Down-regulation   Suppressor   GC              Differentiation                      22
  7                  hsa_circ_0001895                                    Down-regulation   Suppressor   GC              Occurrence                           29
  8                  circZKSCAN1                                         Down-regulation   Suppressor   HCC             Progression                          19
  9                  hsa_circRNA_103809                                  Down-regulation   Suppressor   CRC             Progression                          28
  10                 hsa_circRNA_104700                                  Down-regulation   Suppressor   CRC             Progression                          28
  11                 hsa_circ_104423                                     Down-regulation   Suppressor   GC              Recurrence                           25
  12                 hsa_circ_104916                                     Down-regulation   Suppressor   GC              Recurrence                           25
  13                 hsa_circ_100269                                     Down-regulation   Suppressor   GC              Recurrence                           25
  14                 hsa_circ_0005075                                    Up-regulation     Oncogene     HCC             Growth                               21
  15                 circPVT1                                            Up-regulation     Oncogene     GC              Proliferation                        30
  16                 ciRS7 (Cdr1as)                                      Up-regulation     Oncogene     HCC             Progression                          12
  17                 hsa_circRNA_101308                                  Up-regulation     Oncogene     GC              Recurrence                           25
  18                 ciRS-7 − A                                          Up-regulation     Oncogene     CRC             Progression                          18
  19                 hsa_circRNA_100876                                  Up-regulation     Oncogene     NSCLC           Growth/Progression/Metastasis        27
  20                 hsa_circ_100269                                     Down-regulation   Suppressor   GC              Growth/Recurrence                    33
  21                 circMTO1 (hsa_circRNA_0007874/hsa_circRNA_104135)   Down-regulation   Suppressor   HCC             Progression/Invasion/Growth          42
  22                 circRNA-MYLK                                        Up-regulation     Oncogene     BC              Growth/Metastasis                    31
  23                 circRNA_100338                                      Up-regulation     Oncogene     HCC             Metastasis                           40
  24                 hsa_circ_0003570                                    Down-regulation   Suppressor   HCC             Differentiation/Invasion             39
  25                 Hsa_circ_0014717                                    Down-regulation   Suppressor   GC              Development/ Progression             37
  26                 hsa_circ_0013958                                    Up-regulation     Oncogene     LAC             Invasion                             34
  27                 hsa_circ_100219                                     Down-regulation   Suppressor   Breast Cancer   Occurrence/Progression               36
  28                 hsa_circ_100219,hsa_circ_006054,hsa_circ_406697     Down-regulation   Suppressor   Breast Cancer   Occurrence/Progression               36
  29                 hsa_circ_0006633                                    Down-regulation   Suppressor   GC              Metastasis                           35
  30                 circCCDC66                                          Up-regulation     Oncogene     CRC             proliferation/migration/metastasis   38
  31                 ciRS-7                                              Up-regulation     Oncogene     GC              Growth/Metastasis                    32
  32                 circ-ITCH                                           Down-regulation   Suppressor   HCC             Development/ Progression             41

GC=Gastric Cancer; HCC=Hepatocellular Carcinoma; CRC=Colorectal Cancer; NSCLC=Non-Small Cell Lung Cancer; BC=Bladder Cancer; LAC=Lung Adenocarcinoma.

![Forest plots of sensitivity and specificity and DOR value of diagnostic articles\
(**A**) Forest plots of sensitivity and specificity of diagnostic articles. (**B**) The DOR value of diagnostic articles.](oncotarget-09-11824-g002){#F2}

Subgroup and meta-regression analysis {#s2_5}
-------------------------------------

Stratified analysis was performed based on sample size (\> 100 vs. \< 100) and cancer type (Gastric cancer vs. Colorectal cancer vs. Hepatocellular cancer). In the subgroup with large sample size (\> 100), the pooled sensitivity, specificity and AUC were 0.71(0.63--0.78), 0.76(0.52--0.72) and 0.77(0.73--0.80); while 0.74(0.66--0.80), 0.84(0.75--0.90) and 0.78(0.74--0.82) for small sample size (\< 100). The pooled sensitivity, specificity and AUC in the subgroup of gastric cancer were 0.66(0.57--0.74), 0.80(0.72--0.85) and 0.80(0.78--0.83); while 0.72(0.60--0.82), 0.67(0.58--0.76) and 0.76(0.72--0.79) for colorectal cancer and 0.73(0.59--0.83), 0.79(0.72--0.85), 0.86(0.83--0.89) for hepatocellular cancer, respectively (Figure [3](#F3){ref-type="fig"}, Figure [4](#F4){ref-type="fig"}, Table [4](#T4){ref-type="table"}).

![Forest plots of sensitivity and specificity of diagnostic articles in subgroup analysis\
(**A**) Forest plots of sample size \> 100 subgroup. (**B**) Forest plots of sample size \< 100 subgroup.](oncotarget-09-11824-g003){#F3}

![Forest plots of sensitivity and specificity of diagnostic articles in subgroup analysis\
(**A**) Forest plots of GC subgroup. (**B**) Forest plots of CRC subgroup. (**C**) Forest plots of HCC subgroup.](oncotarget-09-11824-g004){#F4}

###### Results of subgroup and mete-regression analyses in the diagnostic meta-analysis

  Subgroup      Number of studies   Se (95% CI)        Meta-regression (*p*-value)   Sp(95%CI)          Meta-regression (*p*-value)   AUC (95% CI)        Meta-regression (*p*-value)
  ------------- ------------------- ------------------ ----------------------------- ------------------ ----------------------------- ------------------- -----------------------------
  Overall       19                  0.71(0.65--0.77)                                 0.77(0.72--0.81)                                 0.81(0.77--0.84)    
  Sample size                                          0.857                                            0.772                                             0.672
  \> 100        15                  0.71(0.63--0.78)                                 0.76(0.70--0.80)                                 0.77(0.73--0.80)    
  \< 100        4                   0.74(0.66--0.80)                                 0.84(0.75--0.90)                                 0.78(0.74--0.82)    
  Cancer type                                          0.632                                            0.964                                             0.776
  GC            7                   0.66(0.57--0.74)                                 0.80(0.72--0.85)                                 0.80(0.78 - 0.83)   
  CRC           4                   0.72(0.60--0.82)                                 0.67(0.58--0.76)                                 0.76(0.72--0.79)    
  HCC           5                   0.73(0.59--0.83)                                 0.79(0.72--0.85)                                 0.86(0.83--0.89)    

GC=Gastric Cancer; CRC=Colorectal Cancer; HCC=hepatocellular cancer; AUC=Area Under Curve; Se=Sensitivity; Sp=Specificity.

Meta-regression analysis for the subgroups was next conducted. Both the *P* values for sample size and cancer type were \> 0.10, suggesting no significant impact of subgroups on the pooled results.

Sensitivity analysis and publication bias {#s2_6}
-----------------------------------------

Sensitivity analysis was performed to explore the influence of an individual study on the pooled results. No significant change was observed when compared with previous results after removal of each study ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). The threshold effect was also evaluated, which was derived from the differences between sensitivity and specificity. Their Spearman correlation coefficient was −0.52 and *P* = 0.270, indicating no heterogeneity from threshold effect and thus reliability of our results.

Deek's plot was employed to assess the publication bias. Significant publication bias was shown in the study (t = 3.06 and *P* = 0.007, [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}), suggesting that only researches with positive findings were published or accepted.

Prognostic meta-analysis of circRNAs in cancers {#s2_7}
-----------------------------------------------

Study characteristics and quality assessment {#s2_8}
--------------------------------------------

Fifteen records were enrolled in the prognostic meta-analysis, including 11 studies with 1891 samples in all (7 for gastric cancer, 2 for colorectal cancer, 3 for hepatocellular cancer, 1 for non-small cell lung cancer and 1 for breast cancer). Among them, two articles were focused on disease free survival (DFS) and recurrence free survival (RFS); eight were focused on overall survival (OS); the other one was related to both DFS and OS. The main characteristics of prognostic studies were shown in Table [2](#T2){ref-type="table"}. All the samples were selected from Asian tissue. The major detection method for circRNAs expression was quantitative real-time reverse transcription PCR (qRT-PCR), while only one study applied fluorescence *in situ* hybridization (FISH). Newcastle-Ottawa Scale (NOS) was employed to evaluate the quality of enrolled studies, and they were all suggested to be appropriate for meta-analysis ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

Meta-analysis findings {#s2_9}
----------------------

Among the 12 prognosis-related circRNAs, 6 were up-regulated (circPVT1, ciRS-7, hsa_circ_101308, hsa_circ_100876, circRNA-MYLK, circRNA_104135) and 6 were down-regulated (hsa_circ_104423, hsa_circ_104916, hsa_circ_100269, hsa_circ_0007874, hsa_circ_104135, circ_ITCH Table [2](#T2){ref-type="table"}, Table [3](#T3){ref-type="table"}). It was shown that the overall HR with 95% CI for circRNAs expression in caner prognosis was 1.37(0.98--1.75) (Table [5](#T5){ref-type="table"}, Figure [5](#F5){ref-type="fig"}), suggesting poor potentials of circRNAs expression to become biomarkers in OS prediction for cancer patients. Furthermore, the association between circRNAs expression and DFS/RFS was analyzed, and its HR with 95% CI was 2.28(0.77--3.79) (Table [5](#T5){ref-type="table"}, Figure [5](#F5){ref-type="fig"}), also suggesting negative prospects for circRNAs expression to be applied to prediction in DFS/RFS of cancer patients.

###### Results of pooled HR(95% CI) for prognostic articles

  All cancers                OS                   DFS/RFS
  -------------------------- -------------------- --------------------
  HR(95% CI)                 1.37 (0.98--1.75)    2.28 (0.77--3.79)
  Heterogeneity, *P* value   99.2%, *P* = 0.000   99.1%, *P* = 0.000
  Pubbias *P* value          0.917                0.130
  Model                      Random               Random
  N                          1490                 401
  Study Number               11                   4

HR = hazard ratio; CI = confidence interval; OS=Overall Survival; DFS=Disease Free Survival; RFS=Recurrence Free Survival.

![Forest plots of pooled HR (95% CI) of prognostic articles\
(**A**) Pooled HR (95% CI) of OS. (**B**) Pooled HR (95% CI) of DFS/RFS.](oncotarget-09-11824-g005){#F5}

Subgroup and meta-regression analysis {#s2_10}
-------------------------------------

Stratified analysis for OS was performed next. With respect to OS, the HRs with 95% CIs for up-regulated circRNAs and down-regulated circRNAs were 1.85(1.26--2.44) and 0.46(0.32--0.59), respectively (Table [6](#T6){ref-type="table"}, Figure [6](#F6){ref-type="fig"}). Meta-regression analysis for the subgroup have shown that the *P* value was \> 0.10, suggesting no significant impact of subgroup on the pooled results.

###### Results of subgroup and mete-regression analyses in the prognostic meta-analysis of OS

  Subgroup          Number of studies   HR(95% CI)         Meta-regression (*p*-value)
  ----------------- ------------------- ------------------ -----------------------------
  Function                                                 0.116
  Up-regulation     8                   1.85(1.26--2.44)   
  Down-regulation   3                   0.46(0.32--0.59)   

HR=hazard ratio.

![Forest plot of pooled HR (95%CI) of OS in up-regulated group and down-regulated group](oncotarget-09-11824-g006){#F6}

Sensitivity analysis and publication bias {#s2_11}
-----------------------------------------

Sensitivity analysis for DFS/RFS and OS was also conducted. No remarkable change was observed when compared with previous results after removal of each study ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}).

Finally, we used Begg's funnel plot and Egger's test to evaluate the publication bias. Both the *P* values for OS and DFS/RFS were 0.915 and 0.130, respectively, suggesting no significant publication bias exists in the prognostic meta-analysis ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

Accumulating investigations have demonstrated aberrant circRNAs expression may play critical roles in cell proliferation, metastasis and recurrence of cancer. It has also been proven that circRNAs are expressed constantly in tissue, blood and tissue fluid \[[@R43]\]. Therefore, circRNAs may have the potential to be superior biomarkers for cancer diagnosis, prognosis and therapeutic estimate \[[@R6]\]. Recently, numerous studies have been conducted to explore it using relative small sample size. In the present study we collected all the relevant articles published to date and performed a systematic review and meta-analysis on the association of circRNAs expression with cancer diagnosis and prognosis for the first time expecting to get relatively clear conclusions on whether circRNAs have the potential to be biomarkers for diagnosis and prognosis of cancer.

In this study, 18 circRNAs were related to cancer diagnosis, including 3 up-regulated circRNA (hsa_circ_0005075, hsa_circ_0013958, circCCDC66) and 15 down-regulated circRNAs (hsa_circ_002059, hsa_circ_001988, hsa_circ_0001649, hsa_circ_0000190, hsa_circ_0004018, hsa_circ_0001895, circZKSCAN1, hsa_circ_103809, hsa_circ_104700, hsa_circ_003570, hsa_circ_14717, hsa_circ_100219, hsa_circ_006054, hsa_circ_406697, hsa_circ_006633). It is widely believed that circRNAs are with cancer forewarning function. For example, hsa_circ_0000190 \[[@R23]\] and hsa_circ_0002059 \[[@R24]\] have been suggested to be capable of noninvasive markers for GC diagnosis; another research has indicated hsa_circ_0001649 as a potential diagnostic marker for HCC \[[@R26]\]. Our results showed that the overall sensitivity, specificity and AUC of multiple circRNAs were all more than 70%, which were 0.71 (0.65--0.77), 0.77 (0.72--0.81) and 0.81 (0.77--0.84), respectively. Besides, the pooled DOR was 8.37 (6.14--11.39). A valid DOR should be greater than 1, and higher the value is, better the capability of testing discrimination could be obtained. The four above-mentioned parameters demonstrated that circRNAs expression might become promising biomarkers for cancer diagnosis. In stratified analysis, we also found circRNAs expression contributed a relatively high diagnostic specificity to GC and HCC, with the data were 0.80(0.72--0.85) and 0.79(0.72--0.85), suggesting the studied circRNAs might play important roles in the genesis and development of HCC. It has been reported that circZKSCAN1 can inhibit HCC cell proliferation, invasion and metastasis \[[@R19]\], and Cdr1as can promote microvascular infiltration of HCC \[[@R12]\]. Additionally, Chen et al have found hsa-circRNA-000190 in plasma is competent for early GC diagnosis \[[@R23]\]. Therefore, circRNAs could be applied to initial screening for cancer patients, which are beneficial for the improvement of their survival and life quality. Further investigations with larger number of samples are needed to validate these results and to promote clinical application of circRNAs as noninvasive biomarkers for cancer diagnosis.

Twelve prognosis-related circRNAs were involved in the meta-analysis, in which 6 were up regulated (circPVT1, ciRS-7, hsa_circ_101308, hsa_circ_100876, circRNA-MYLK, circRNA_104135) and 6 were down regulated (hsa_circ_104423, hsa_circ_104916, hsa_circ_100269, hsa_circ_0007874, hsa_cir_104135, circ-ITCH). A circRNAs combination was found to be associated with poor prognosis for GC patients, containing the three down-regulated circRNAs and one up-regulated circRNA, hsa_circ_101308. And another circRNAs combination including hsa_circ_0007874 and hsa_circ_104135 was related to more benign prognosis for HCC patients. Apart from them, the up-regulation of ciRS-7, hsa_circ_100876, circRNA-MYLK, circRNA_100338 was also suggested poor prognosis, while circPVT1, hsa_circ_100269, hsa_circ_0007874, hsa_circ_104135 and circ-ITCH indicated a better outcome. Generally speaking, oncogenes can elevate the susceptibility to cancer and confer to poor survival. However, some molecules were malignant could lead to better prognosis or higher sensitivity to chemotherapy \[[@R44]\], which was just demonstrated on circPVT1 in our study. Actually, it remains controversial whether circRNAs could serve as prognostic markers for OS or DFS/RFS. Weng et al found ciRS-7-A expression was associated with a worse OS of colorectal cancer \[[@R18]\]; while Jie Chen et al reported that circPVT1 contributed better OS to GC patients \[[@R30]\]. Similar phenomenon could also be discovered in the investigations about DFS/RFS \[25; Chen, 2017 \#44\]. In our stratified analysis, we found that the overall HR(95% CI) were 1.85 (1.26, 2.44) and 0.46 (0.32, 0.59) for up-regulated circRNAs and down-regulated circRNAs, respectively, suggesting that the up-regulated circRNAs can predict poor cancer prognosis and the down-regulated circRNAs may play the role of better cancer prognosis predictor. Notably, the prospects of circRNAs for clinical application will be quite broad if they are prognostic markers for cancer. Due to the stable expression of circRNAs in various body fluids, they could provide more effective information for clinical prediction in the perioperative period when compared with clinical parameters such as tumor size and clinicopathologic stage. Further large-scale investigations are needed to identify novel circRNAs and to comprehensively and objectively explore their clinical roles as promising biomarkers for cancer prognosis.

Several limitations should be acknowledged. First, all the samples in our study were selected from Asian population and the detection method for circRNAs expression was major in qRT-PCR. Single sample source and technology might mask the possible impacts of ethnicity and experimental methods on the results. Second, some literatures was not successfully extracted due to the no response of the investigators, which would produce some bias for the selection of the recruitment. Moreover, the sample size involved in the meta-analysis was still relatively small limited by few available articles to date.

In summary, as a type of stably expressed molecules, circRNAs could be promising biomarkers for diagnosis and prognosis of cancers. More association studies focusing on circRNAs expression with cancer are needed to further explore the practical values of circRNAs expression on clinical diagnosis and treatment.

MATERIALS AND METHODS {#s4}
=====================

This study was carried out on the basis of Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) \[[@R45]\].

Search strategy {#s4_1}
---------------

A literature search of PubMed and Web of Science was performed for studies related to the association of circRNAs with cancer diagnosis or (and) prognosis up to September 10th, 2017, using the following key words: "circRNA cancer", "circRNA carcinoma", "circRNA tumor", "circRNA neoplasm", "circularRNA cancer", "circularRNA carcinoma", "circularRNA tumor", "circularRNA neoplasm".

Selection criteria {#s4_2}
------------------

Two reviewers (Hanxi Ding and Qian Xu) evaluated the eligibility of retrieved articles independently. All selected studies met the following criteria: (1) Cases were histopathologically diagnosed as cancer; (2) Information of control groups was available; (3) CircRNAs were used for cancer diagnosis or prognosis; (4) The effect indicators contained AUC, sensitivity, specificity or OS, DFS, RFS, HR and 95% CI; (5) Data was sufficient for quantitative analysis. The exclusion criteria were: (1) Duplicate studies; (2) Reviews; (3) Not related to human or cancer; (4) Irrelevant to the study subject; (5) Insufficient data for quantitative analysis. Two reviewers reached consensus regarding all items.

Data extraction {#s4_3}
---------------

Two investigators (Hanxi Ding and Qian Xu) independently extracted the data according to critical criteria. The following information was obtained from each article: first author's name, publication year, origin country and ethnicity, circRNAs' name, cancer type and stage, total number of cases, sample source, and detection method. Diagnostic indicators included sensitivity, specificity and AUC; Prognostic indicators were survival and HR with 95% CI for DFS or OS. When HRs with 95CIs were not presented in the study, they were extracted from Kaplan-Meier survival curves using a method introduced by Tierney et al \[[@R46]\].

Quality assessment {#s4_4}
------------------

Quality assessment of diagnostic accuracy studies-2 (QUADAS-2) was employed to evaluate the quality of enrolled studies. Prognostic studies quality was assessed based on the Newcastle-Ottawa Scale \[[@R47]\].

Statistical analysis {#s4_5}
--------------------

All analyses were conducted using Stata software, version 11.0. *P* \< 0.05 was considered as statistically significant.

Sensitivity, specificity and AUC were involved in the diagnostic meta-analysis. The pooled parameters were all estimated by continuous meta-analysis model. The area under summary receiver operator characteristic curve (SROC) was calculated to evaluate the diagnostic efficacy. Inter-study heterogeneity was examined with the I^2^ statistic \[[@R48]\]. To explore the possible source of heterogeneity, stratified analysis based on cancer type and sample size as well as meta-regression were performed \[[@R49]\]. Deek's funnel plot was employed to assess the publication bias \[[@R50]\]. Sensitivity analysis was also conducted.

In the prognostic meta-analysis, the pooled OR with 95% CI was calculated to evaluate the association between circRNAs expression and survival of cancer patients in both fixed-effect and random-effect models. Cochran's Q test and I^2^ statistic were used to judge the inter-study heterogeneity \[[@R51]\]. We pooled the results using fixed-effect model when *P* \> 0.10 and I^2^ \< 50%, suggesting an absent heterogeneity \[[@R52]\]; otherwise the random-effect model would be chose. Begg's funnel plot was employed to assess the publication bias \[[@R53]\]. Sensitivity analysis was also conducted.
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GC

:   Gastric Cancer

HCC

:   Hepatocellular Carcinoma

CRC

:   Colorectal Cancer

NSCLC

:   Non-Small Cell Lung Cancer

AUC

:   Area Under Curve

ROC

:   receiver operating characteristic curve

Se

:   Sensitivity

Sp

:   Specificity

DFS

:   Disease Free Survival

RFS

:   Recurrence Free Survival

OS

:   Overall Survival
